CTMX Q3 2024 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M+26.7% YoY

Gross Profit

$33M100.0% margin

Operating Income

$4M12.3% margin

Net Income

$6M17.2% margin

EPS (Diluted)

$0.07

QoQ Revenue Growth

+33.1%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$139M

Total Liabilities

$162M

Stockholders' Equity

-$23M

Cash & Equivalents

$41M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$26M	+26.7%
Gross Profit	$33M	$25M	+34.0%
Operating Income	$4M	$11M	-62.9%
Net Income	$6M	$3M	+91.7%